Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Completed Phase 2 Interventional Results available

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

NCT03478982
View directory record Official record
Conditions
Epilepsy
Interventions
Staccato Alprazolam, Placebos
Drug
Lead sponsor
Engage Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 22, 2026, 9:26 PM EDT
Enrolling by invitation No phase listed Observational

Epilepsy Emergency Department High Utilizer Program

NCT07663240
View directory record Official record
Conditions
Epilepsy, Uncontrolled Seizures
Interventions
CHW-Led Transition-of-Care Intervention
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Completed No phase listed Observational

Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings

NCT06093490
View directory record Official record
Conditions
Absence Epilepsy, Childhood, Absence Seizures, Absence Epilepsy, Epilepsy in Children, Staring, Seizures
Interventions
Eysz Hyperventilation Recorder
Device
Lead sponsor
Eysz, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
65 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ketogenic Diet Program for Epilepsy

NCT02497105
View directory record Official record
Conditions
Epilepsy
Interventions
Ketogenic Diet
Other
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
6 Months to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 22, 2026, 9:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Retraining and Control Therapy (ReACT) R33 Phase

NCT06007053
View directory record Official record
Conditions
Convulsion, Non-Epileptic
Interventions
ReACT, Supportive Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
11 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 4 Interventional Results available

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

NCT00955357
View directory record Official record
Conditions
Partial Epilepsies
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
17 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
40
States / cities
Irvine, California • Rancho Mirage, California • Clearwater, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 22, 2026, 9:26 PM EDT
Recruiting No phase listed Observational

De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information

NCT05140265
View directory record Official record
Conditions
Epilepsy, Status Epilepticus, Seizures
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2014 · Synced Oct 22, 2026, 9:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Psychiatric Correlates of Psychogenic Movement Disorder and Non-Epileptic Seizure

NCT00255411
View directory record Official record
Conditions
Psychogenic Movement Disorders, Non-epileptic Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

NCT00866775
View directory record Official record
Conditions
Epilepsy With Simple or Complex Partial Onset Seizures
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 1 Interventional Results available

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

NCT02724423
View directory record Official record
Conditions
Acute Repetitive Seizures
Interventions
NRL-1
Drug
Lead sponsor
Neurelis, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 22, 2026, 9:26 PM EDT
Completed No phase listed Observational

Metabolic Abnormalities in Children With Epilepsy

NCT00001325
View directory record Official record
Conditions
Generalized Epilepsy, Infantile Spasms, Metabolic Disease, Partial Epilepsy, Seizures
Interventions
18 FDG
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 9:26 PM EDT
Enrolling by invitation Not applicable Interventional

Baseline Performance and Fitting Parameters for Sonova Products

NCT05859568
View directory record Official record
Conditions
Hearing Loss, Ear Diseases, Hearing Disorders, Otolaryngological Disease
Interventions
Pinna-located microphone, Pinna-simulated microphone algorithm
Device
Lead sponsor
Advanced Bionics
Industry
Eligibility
8 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Valencia, California
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

NCT01397968
View directory record Official record
Conditions
Partial Epilepsy
Interventions
YKP3089, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
16
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 22, 2026, 9:26 PM EDT
Enrolling by invitation Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

NCT07353918
View directory record Official record
Conditions
Epilepsy (Treatment Refractory), Epilepsy Comorbidities
Interventions
Low-intensity Focused Ultrasound, Sham
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Terminated Phase 3 Interventional Results available

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690
View directory record Official record
Conditions
Epilepsy, Lennox-Gastaut Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 3 Interventional Results available

RNS® System Pivotal Study

NCT00264810
View directory record Official record
Conditions
Epilepsy
Interventions
RNS® System implantation, RNS® System responsive stimulation
Procedure · Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 2 Interventional

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

NCT06769659
View directory record Official record
Conditions
Epilepsy, Generalized, Epilepsy, Absence
Interventions
NPT 2042, Placebo
Drug · Other
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617
View directory record Official record
Conditions
Stereotypical Prolonged Seizures
Interventions
Staccato alprazolam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
48
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Active, not recruiting No phase listed Observational

Neural Circulatory Control and SUDEP Risk.

NCT02813980
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Terminated Not applicable Interventional

Transnasal Induction of Normothermia for Neurogenic Fever

NCT06038513
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Seizures, Metabolic Encephalopathy
Interventions
Transnasal Thermal Regulating Device
Device
Lead sponsor
CoolTech LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 22, 2026, 9:26 PM EDT
Completed Phase 1 Interventional

Preventing Brain Injury in Infants With Congenital Heart Disease

NCT01426542
View directory record Official record
Conditions
Cyanotic Congenital Heart Disease
Interventions
Topiramate, No medication, but routine heart surgery
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 2 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 22, 2026, 9:26 PM EDT
Recruiting Not applicable Interventional

Quantifying Bone and Skin Movement in the Residual Limb of Individuals With Transtibial Amputation Using Dynamic Stereo X-Ray

NCT05287646
View directory record Official record
Conditions
Amputation, Lower Limb
Interventions
Suction Suspension First, Elevated Vacuum Suspension First
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 9:26 PM EDT